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HPV-based screening provides greater protection against cervical cancer 21 
(CC) than cytology-based strategies. Currently, several molecular diagnostic 22 
assays for the detection of human papillomavirus (HPV) are available. In this 23 
study, we analyzed 5 different HPV testing and genotyping techniques (Hybrid 24 
Capture 2 [HC2; Qiagen, Hilden, Germany ], AnyplexTMII HPV28 [Anyplex; 25 
Seegene, Seoul, Korea], Linear Array [Roche, Branchburg, NJ, USA], 26 
GP5+/6+ PCR-EIA-RH [Labo Bio-medical Products, Rijswijk, The Netherlands]  27 
and CLART2 [Genomica, Madrid, Spain]) in 295 women referred to the 28 
hospital Colposcopy Clinic from 2007 to 2008 due to positive HPV test results 29 
or an abnormal Pap test. DNA extraction for HPV genotyping was performed 30 
in cervical sample specimens after Pap test and HPV detection by HC2. The 31 
inclusion criteria were: (1) adequate cervical sampling with sufficient material 32 
for the Pap test and HPV detection and genotyping, and (2) colposcopically-33 
directed biopsy and/or endocervical curettage. HC2 showed the highest 34 
sensitivity for high-grade squamous intraepithelial lesion and CC (HSIL+) 35 
detection (96.1%), but all the HPV genotyping tests showed a higher 36 
specificity. (Anyplex 86.8%; Linear Array 86.0%; GP5+/6+ 78.8%; CLART2 37 
76.5%). The agreement between HC2 results and the other techniques was 38 
similar: (82.4%, kappa = 0.650 for Anyplex; 83.4%, kappa = 0.670 for Linear 39 
Array, 79.93%, kappa = 0.609 for GP5+/6+ and 82.4%, kappa=0.654 for 40 
CLART2. HPV 16 and/or 18 infection was a risk factor for underlying HSIL+ in 41 
the univariate analysis. Anyplex showed the highest risk of underlying HSIL+ 42 
after positive HPV 16 and/or 18 tests (OR 31.1; 95% IC 12.1-80.0). 43 
 44 
  45 
INTRODUCTION 46 
High-risk human papillomaviruses (hr-HPV) are the causative agents of 47 
cervical cancer (CC) and its precursors.  (1;2) A consequence of this well-48 
established causal link between hr-HPV infection and CC development  (3) is 49 
the introduction of hr-HPV DNA testing in CC screening programs, initially 50 
implemented as a complement to the Pap test and, in the last few years, as 51 
the first line screening test. (4;5) hr-HPV DNA testing has shown a higher 52 
sensitivity than cytology in detecting high-grade squamous intraepithelial 53 
lesions or CC (HSIL+)  (6-8), and there is evidence that HPV-based screening 54 
provides better protection against CC than Pap test-based strategies.  (9) hr-55 
HPV DNA testing is also the recommended method in the follow-up of patients 56 
treated for HSIL+, since it is more accurate than repeated cytology in 57 
diagnosing residual disease or relapse.  (10;11) 58 
Currently, several molecular diagnostic assays for the detection of HPV 59 
are available. Hybrid Capture 2 (HC2, Qiagen, Hilden, Germany) was the first 60 
technique approved by the US Food and Drug Administration (FDA) and has 61 
become the reference test against which the newly developed HPV assays 62 
have to be assessed.  (12) The Cervista HPV HR Test (Hologic, Madison, WI, 63 
USA)  (13), and the Roche Cobas 4800 HPV Test (Roche, Branchburg, NJ, 64 
USA) have also received FDA approval for the detection of hr-HPV in CC 65 
screening  (14;15), and the Abbott RealTime High-Risk HPV test (Abbott 66 
Molecular, Des Plaines, IL, USA) has obtained CE Marking.  (16) All these 67 
tests, designed for screening, simultaneously detect different hr-HPV 68 
genotypes and do not allow specific typing, although some (Roche Cobas 69 
4800 HPV Test, Abbott RealTime High-Risk HPV) provide specific genotyping 70 
information for HPV 16 and 18, which are considered the HPV types with the 71 
highest carcinogenic risk.  (17-20) 72 
A number of commercially available techniques allow specific genotype 73 
identification: INNO-LiPA HPV Genotyping Extra kit (Innogenetics, Ghent, 74 
Belgium), CLART2 (Genomica, Madrid, Spain), Linear Array assay (Roche, 75 
Branchburg, NJ, USA), GP5+/6+ PCR-EIA-RH (GP5+/6+, Labo Bio-medical 76 
Products, Rijswijk, The Netherlands), Anyplex TMII HPV28 (Anyplex, 77 
Seegene, Seoul, Korea). These techniques have been approved within the 78 
European Union (CE Marking) and have shown to be useful in epidemiological 79 
studies to improve the triage of HPV-positive women by single type risk 80 
stratification,  (20;21) and the follow-up of persistent infection.  (18;21)  81 
The aim of the present study was to compare the analytical and clinical 82 
performance of Anyplex, Linear Array, GP5+/6+ and the CLART2 assay with 83 
HC2, which is the reference test routinely used in many laboratories for HPV 84 
detection in women referred to colposcopy. 85 
MATERIAL AND METHODS 86 
Study design and patient selection 87 
This transversal study was performed at the Hospital Clinic of Barcelona, 88 
Spain. Data from all women referred to the hospital from 2007 to 2008 due to 89 
a positive hr-HPV test result or a Pap test result of atypical squamous cells, 90 
atypical glandular cells, low-grade squamous intraepithelial lesions (LSIL), 91 
HSIL, or CC within the 6 months previous to admission were reviewed.  92 
From all women referred in this period we selected women who fulfilled 93 
the following inclusion criteria: (1) adequate cervical sampling with sufficient 94 
material for cytology (Pap test) and all the HPV tests (HC2, Anyplex, CLART2, 95 
Linear Array assay, and GP5+/6+); and (2) adequate colposcopy examination 96 
with at least a colposcopically-directed biopsy and/or endocervical curettage. 97 
A total of 295  women met the inclusion criteria and were therefore included in 98 
the study. 99 
The study was approved by the institutional Ethical Review Board of the 100 
Hospital Clinic. All patients provided written consent for the use of biological 101 
specimens for research purposes after the clinical procedures were 102 
completed.  103 
Patient Management  104 
Prior to the colposcopy procedure, a cervical sample was collected from 105 
all the women using a cytobrush, which was transferred to PreservCyt solution 106 
(Hologic, Marlborough, MA, USA). The first part of the sample was used for 107 
ThinPrep liquid-based cytology. The residual material was used first for hr-108 
HPV testing by HC2 and second to test the different assays for HPV detection 109 
and genotyping. 110 
Colposcopy was performed using an Olympus Evis Exera II CV-180 111 
colposcope (Olympus, Barcelona, Spain) after preparing the cervix with 5% 112 
acetic acid. A colposcopically-directed biopsy was taken in all patients on the 113 
identificaton of an abnormal area.  (22;23) When the transformation zone was 114 
not completely visible, endocervical curettage using a Kervokian curette was 115 
also performed. A random biopsy from the transformation zone was performed 116 
in all the women with a completely visible transformation zone having no 117 
colposcopic abnormalities.  (24;25) 118 
Liquid-based cytology and histological diagnosis 119 
Thin-layer cytology slides were prepared using the Thinprep T2000 slide 120 
processor (Hologic) and stained using the Papanicolaou method. Cytology 121 
slides were evaluated by a cytotechnologist and confirmed by a pathologist 122 
using the revised Bethesda nomenclature.  (26) Formalin-fixed, paraffin-123 
embedded 4-mm sections were routinely stained with hematoxylin and eosin 124 
(H&E). All the histological samples were reviewed by one of the authors (JO) 125 
to confirm the presence or absence of cervical lesion and its grade. The 126 
histological diagnoses were established using pure morphologic criteria based 127 
on the H&E-stained sections, with no knowledge of HPV status or the cytology 128 
result. The LAST nomenclature was used for the histological diagnosis.  (27) 129 
Routine HPV detection (hybrid capture II) 130 
Detection of hr-HPV was performed in cytological samples. Initially hr-131 
HPV detection was undertaken with the Hybrid Capture 2 (HC2) system 132 
(Qiagen, Hilden, Germany) in the samples collected in liquid-based media 133 
(PreservCyt). This test detects the following genotypes: 16, 18, 32, 34, 36, 39, 134 
45, 51, 52, 56, 58, 59, and 68. A relative light unit of 1 (1.0 pg/mL) was used 135 
as the cut-off to classify a specimen as positive for hr-HPV.  (28)  136 
Detection of HPV by genotyping tests  137 
 138 
After the initial processing that included the Pap test and HC2 testing the 139 
residual material was centrifuged and the pellets stored at -80ºC until 140 
processing. For all the other genotyping tests DNA extraction was performed 141 
using 250µL of the cervical sample specimen to obtain 100 µL of eluate with 142 
the QIAamp MinElute Virus Spin kit (QIAgen Inc., Valencia, CA, USA) 143 
according to the manufacturer’s protocol. DNA yields were quantified 144 
spectrophotometrically using the Nanodrop ND-1000 (NanoDrop 145 
Technologies, USA). A negative and a positive internal control were used in 146 
each genotyping assay according to the manufacturer’s procedure. All 147 
genotyping assays were tested twice with each sample. A sample was 148 
considered invalid for an specific test when both results were invalid.  149 
Anyplex II HPV28 (Anyplex) was performed according to the 150 
manufacturer’s instructions with using 5 μl DNA in each of the two 20μl 151 
reaction mixtures with primer set A or B and a CFX96 real-time thermocycler 152 
(Bio-Rad, Hercules, CA, USA). A-set has 14 hr-HPV types (16, 18, 31, 33, 35, 153 
39, 45, 51, 52, 56, 58, 59, 66, and 68) and B-set covers five HR and nine LR 154 
types (26, 53, 69, 73, 82, 6, 11, 40, 42, 43, 44, 54, 61, and 70). Anyplex uses 155 
the Tagging Oligonucleotide Cleavage and Extension (TOCE) technology 156 
(Seegene, Seoul, Korea) a novel approach that enables the detection of 157 
multiple targets in the same fluorescence channel of real-time PCR. The L1 158 
gene of HPV and human beta-globin was simultaneously co-amplified as an 159 
internal control to monitor DNA purification efficiency, PCR inhibition, and cell 160 
adequacy.  (29) The thermal cycler conditions consisted of an initial incubation 161 
at 50ºC for 4 minutes, denaturation at 95ºC for 15 minutes, followed by 50 162 
cycles of denaturation at 95ºC for 30 seconds, annealing at 60ºC for 1 minute, 163 
and elongation at 72ºC for 30 seconds. 164 
Linear Array HPV genotyping test (Linear Array). This assay recognizes 165 
the following HPV types: hr-HPV types 16, 18, 31, 33, 35, 39, 43, 44, 45, 51, 166 
52, 56, 58, 59, and 68 and lr-HPV types 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 167 
64, 66, 67, 69, 70, 71, 72, 81, 73, 82, 83, 84, and IS39 and CP6108.  (30) 168 
Amplification, hybridization, and detection steps were performed as 169 
recommended by the manufacturer. Briefly, ten μL of extracted DNA was 170 
employed in the PCR reaction. PCR was performed in a final reaction volume 171 
of 100 μl. The mixture was incubated for 2 minutes at 50°C and for 9 minutes 172 
at 95°C, followed by 40 cycles of denaturation at 95ºC for 30 seconds, 173 
annealing at 95°C for 30 seconds, and elongation at 72ºC for 1 minute. 174 
GP5+/6+ PCR-EIA-RH (GP5+/6+). Ten μL of isolated DNA were amplified by 175 
the GP5+/6+ PCR, and hr-HPV was detected by the EIA (Diassay, Rijswijk, 176 
The Netherlands) according to the manufacturer’s instructions. (31) GP5+/6+ 177 
PCR was performed in a total volumen of  50 μl. The mixture underwent 4 178 
minutes denaturation step at 94°C, followed by 40 cycles of denaturation at 179 
94°C for 20 seconds, annealing at 40 °C for 2 minutes and a chain elongation 180 
step at 72°C for 1 minutes. The first cycle was preceded by a 4 min 181 
denaturation at 94 °C and the last cycle was extended by a 4 min elongation at 182 
72 °C. (32) Fourteen hr-HPV types can be targeted with the GP5+/6+ test: 183 
HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. After GP5+/6+ 184 
PCR, EIA was performed. Three times the mean OD of the PCR negative 185 
controls (OD ≤0.120) was used as the cut-off value to classify samples as 186 
positive for HPV. This assay does not identify HPV genotypes individually. 187 
Thus, next, the EIA-positive GP5+/6+ amplimers were genotyped by Reverse 188 
Hybridization using Line Probe Assay, according to the manufacturer’s 189 
instructions. Briefly, ten μl of the biotinylated products of PCR were mixed in 190 
test troughs and incubated at room temperature for 5 minutes after that, 1ml of 191 
the prewarmed (37°C) hybridization solution and one strip was added to each 192 
trough. Hybridization was performed for 1hour at 50ºC in a closed water bath 193 
with back-and-forth shaking. The strips were washed twice with 1ml of wash 194 
solution, at room temperature for 20 seconds and once at 50°C for 30 minutes. 195 
After the washing step, strips were rinsed twice with 1ml of a standard rinse 196 
solution.  (33) Strips were incubated on a rotating platform with an alkaline 197 
phosphatase-labeled streptavidin conjugate diluted in a standard conjugate 198 
solution for 30minutes at 25°C. Strips were then washed twice with 1ml of 199 
rinse solution and once with standard substrate buffer, and color development 200 
was initiated by addition of 5-bromo-4-chloro- 3-indolylphosphate and nitroblue 201 
tetrazolium to 1ml of substrate buffer.  (33) After 30minutes of incubation at 202 
room temperature, the color reaction was stopped by aspiration of the 203 
substrate buffer and addition of distilled water. After drying, the strips were 204 
visually interpreted using a grid. 205 
CLART HPV2 Assay (CLART2). This test uses biotinylated MY09/11 206 
consensus primers and is able to detect 35 HPV types, including 20 hr-HPV 207 
types (type 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 208 
73, 82, 85) and 15 lr-HPVs (6, 11, 40, 42, 43, 44, 54, 61, 62, 71, 72, 81, 83, 209 
84, 89). The test was performed according to the manufacturer’s instructions.  210 
(34;35) Briefly, five μL of eluted DNA were added to 45 μL of Genomica 211 
Master Mix for HPV testing. After an initial denaturation step at 95ºC for 5 212 
minutes, reaction mixtures underwent 40 cycles of denaturation at 94°C for 30 213 
seconds followed by annealing at 55ºC for 60 seconds, and elongation step at 214 
72ºC for 90 seconds, and finally a cycle of 4ºC for 8 minutes. Detection of 215 
PCR product was made by a low-density microarray platform, CLART (Clinical 216 
Array Technology). Results were automatically analyzed in CLART Human 217 
Papillomavirus 2 specific software as well as manually surveyed using the 218 
CLART grid (Genomica). 219 
Final Diagnosis 220 
The diagnosis of CC and HSIL was established in all cases after 221 
histological confirmation. Diagnosis of LSIL was determined based on either 222 
histological confirmation or the LSIL result in the Pap test. Women with a 223 
negative biopsy and normal Pap test results were classified as negative for 224 
intraepithelial lesion or malignancy. 225 
Data analysis  226 
Data analyses were performed with the SPSS version 18.0 (SPSS Inc, 227 
Chicago, IL, USA). The statistical methods used in the study were mostly 228 
descriptive. The Student t-test or analysis of variance was used to compare 229 
quantitative variables. Qualitative variables were compared with the Chi 230 
square test. A p value ≤ 0.05 was considered statistically significant. 231 
Sensitivity, specificity and positive (PPV) and negative predictive values (NPV) 232 
were determined by comparing the results of the HPV testing assays with the 233 
final diagnoses. For these values, 95% confidence intervals (CI) were 234 
assessed using either a binomial or normal distribution according to the data. 235 
The κ value and its standard deviation (SD) were calculated as a measure of 236 
agreement for positive testing and between the HPV genotypes observed in 237 
the different tests.  238 
HPV genotype concordance among the different HPV genotyping tests 239 
was analyzed and classified as follows: 1) identical if all genotypes were 240 
identified by the different tests; 2) concordant when the analysis showed at 241 
least one identical genotype; and 3) different if there were no similarities 242 
between the genotypes found.  243 
Univariate logistic regression was performed to identify the risk of a 244 
positive HPV test and a positive result for HPV16 and/or 18 for underlying 245 
HSIL+, with the odds ratio (OR) reported as an estimate of relative risk. 246 
RESULTS 247 
The mean age of the women included in the study was 37.4 ± 13.1 years 248 
(range 15-78). The final diagnosis after the completion of the study was CC in 249 
9 women (3.1%; 6 squamous cell carcinomas, 3 adenocarcinomas), HSIL in 250 
44 women (14.9%), LSIL in 78 women (26.4%), and negative in 164 women 251 
(55.6%). Of the 78 women classified as LSIL, 43 (55.1%) had a histological 252 
diagnosis, whereas in 35, the diagnosis was established on the basis of LSIL 253 
cytology with a negative biopsy.  254 
Table 1 shows the number of valid samples for each assay and the 255 
percentage of women with positive HPV results by HC2 and the four HPV 256 
genotyping tests according to each final diagnostic category. The agreement 257 
between HC2 results and the results obtained with the other techniques 258 
(positive vs. negative testing) was similar: 82.4% (95%CI= 77.6-86.4%), kappa 259 
= 0.650 ± 0.044 for Anyplex; 83.4% (95% CI= 78.7-87.3%), kappa = 0.670 ± 260 
0.043 for Linear Array, 79.93% (95%CI=75.0-94.1%), kappa = 0.609 ± 0.042 261 
for GP5+/6+ and 82.4% (95%CI 77.1-86.7%), kappa=0.654 ± 0.046 for 262 
CLART2.  263 
Table 2 shows the sensitivity, specificity and PPV and NPV for the 264 
detection of HSIL+ with all the molecular HPV tests. Among the four 265 
genotyping tests Anyplex showed the highest sensitivity for HSIL and CC 266 
detection. 267 
Among the positive cases, 42.0% (58 out of 138 positive cases) showed 268 
multiple HPV types with Anyplex, 44.0% (62/141) with Linear Array, 20.4% 269 
(19/93) with GP5+/6+ and 40.7% (44/108) with the CLART2 test. The 270 
differences between the rates of multiple-infected lesions were statistically 271 
significant (Supplementary tables 1-6). 272 
The genotype distribution among the Anyplex positive cases identified by 273 
each specific test is shown in Table 3. The comparison of the genotype 274 
distribution between Anyplex and Linear Array in the 125 cases positive for 275 
both techniques showed identical genotypes in 73 (58.4%) samples, 276 
concordant genotypes in 47 (37.6%) and different genotypes in 5 (4.0%). Both 277 
tests were negative in 133 samples. The comparison between Anyplex and 278 
GP5+/6+ in the 86 samples positive for both assays showed identical 279 
genotypes in 53 (61.6%), concordant results in 31 (36.1%) and different HPV 280 
genotypes in 2 (2.3%). One hundred forty-five samples were negative for both 281 
tests. On comparing Anyplex and CLART2, both tests were positive in 103 282 
samples. Identical genotypes were found in 61 (59.2%), concordant genotypes 283 
in 39 samples (37.9%) and different genotypes in 3 (2.9%). Both tests were 284 
negative in 106 samples.  285 
Table 4 shows the risk of a positive hr-HPV test for underlying HSIL+ 286 
lesion according to the HC2 test and the risk of a positive result for HPV non 287 
16 non 18 and positive result for HPV 16 and/or 18 for underlying HSIL+ lesion 288 
according to the different assays. Positive HPV testing, especially positive 289 
results for HPV 16 or 18 were associated with the risk of an underlying HSIL+ 290 
lesion. Anyplex showed the highest risk of underlying HSIL+ results after a 291 
positive result for the HPV 16 or 18 test (OR 31.1; 95% CI 12.1-80.0). 292 
DISCUSSION 293 
The present study compared different HPV tests in a routine diagnostic 294 
setting. HC2 showed the highest sensitivity for HSIL+ detection while the 295 
sensitivity of Anyplex and Linear Array was 90% of that shown by the HC2 296 
test, (36) and they could therefore be considered candidate tests for CC 297 
screening according to the international guidelines for HPV test validation. On 298 
the other hand, CLART2 and GP5+/6+ showed a lower sensitivity, although 299 
the latter showed the highest specificity. Patients under 30 years of age 300 
present a high prevalence of HSIL lesions, (15) most of which regress and are 301 
not the objective of CC screening strategies. Thus, the lower sensitivity of 302 
CLART2 and GP5+/6+ could be helpful in this specific age group. All the HPV 303 
tests showed a higher sensitivity than the cited 51% benchmark of cytology 304 
sensitivity as a stand-alone test.  (9;37) All HPV genotyping tests showed a 305 
higher specificity than HC2 for the detection of HSIL+. The similar clinical 306 
sensitivity and superior or equal specificity of the four HPV genotyping tests 307 
compared to HC2, observed in primary screening, is in agreement with the 308 
findings from previous studies on its performance in the triage of women with 309 
minor cytological abnormalities.  (12;29;36;38) 310 
The agreement in terms of positivity/negativity of the different HPV 311 
genotyping tests compared with HC2 was about 80% or higher. The high 312 
agreement between the tests is in line with previous comparative reports.  (38-313 
43) Similarly, genotype concordance was over 80%. Different HPV types were 314 
found in less than 5% of the HPV positive samples. Despite the different HPV 315 
types included in each test and the differences in terms of sensitivity and 316 
specificity, high concordance has been also reported between genotype 317 
distribution in previous studies.  (38;39;41-44) 318 
In the present study, the rate of multiple HPV infections significantly 319 
varied from 20.4% to 44.0% depending on the test used. This is in line with 320 
previous studies comparing different methods for HPV typing and describing 321 
considerable differences in the multiple infection rates of the individual tests. 322 
These series have shown that 15% to 50% of women with prevalent SIL of all 323 
grades have multiple hr-HPV genotypes. (45-47) The clinical significance of 324 
multiple HPV infections has been analyzed previously.  (48;49) However, only 325 
limited conclusions can be drawn from HPV typing in cytology, as it includes 326 
all infections present on the cervico-vaginal surface including transforming 327 
infections related to HSIL lesions, transient infections, and possibly sexually 328 
deposited HPV DNA.  (46) 329 
In line with the data of the present study, several previous reports have 330 
shown an increased risk of underlying or developing HSIL+ after an HPV 16 331 
and/or 18 infection. (18;20;21;50) Indeed, recent guidelines recommend HPV 332 
genotyping for HPV 16 and 18 as a triage strategy for women testing positive 333 
for HPV.  (5;51) Recently, Cuzick et al. reported that the most common hr-334 
HPV detected in women with HSIL histological lesions was HPV16.  (52) This 335 
is in line with previous reports and with the present study, in which HPV 16 336 
was the HPV type most frequently identified with all the techniques. (18;21) 337 
 The main strength of our study is that it includes a series of women 338 
studied according to a well-defined protocol routine, which included liquid-339 
based cytology, hr-HPV testing, and colposcopy with directed biopsies, with 340 
endocervical curettage being performed in the case of a non visible 341 
transformation zone. Thus, the results of HPV testing and genotyping of the 342 
cytology sample are directly correlated with a colposcopy and a histological 343 
sample. The implementation of highly sensitive analytical HPV assays could 344 
detect most underlying high-grade disease, but it can also lead to a large 345 
proportion of clinically irrelevant positive results, which would result in 346 
unnecessary diagnostic procedures and treatments, increased costs and 347 
psychological distress in healthy women. Thus, as previously stressed, clinical 348 
sensitivity is more relevant than analytical sensitivity in CC screening, and any 349 
new technique should be validated in a clinical setting. Another strength of the 350 
present study is that all the genotyping tests were performed in all the women 351 
included, thereby avoiding bias in the analysis of clinical performance of the 352 
tests studied.  353 
This study has some possible limitations. No follow-up data was 354 
available; thus the possible relation between specific type of hr-HPV detected 355 
by a test and the risk of developing HSIL+ could not be assessed. It has been 356 
suggested that HPV 16 and/or 18 can identify women at higher risk of 357 
underlying HSIL+ lesions  (51;53) but they are also related to the risk of 358 
developing high-grade disease in the follow-up.  (18;21) Likewise, HPV 31, 33 359 
or 45 have been related to a higher risk of HSIL+.  (18;20;21) However, the 360 
current guidelines do not support different follow-up algorithms according to 361 
the HPV genotype isolated in a cervical lesion. Another possible limitation is 362 
related to the accuracy of colposcopy to guide biopsy sampling, namely when 363 
single biopsy from the most worrisome lesion was taken  (24) which might 364 
miss an underlying HSIL lesion at initial evaluation in a proportion of women. 365 
In spite of this possible limitation, colposcopy is currently considered the gold 366 
standard to guide biopsy sampling to confirm the diagnosis in these patients.  367 
(24) 368 
In conclusion, this study show that most of the HPV tests currently 369 
available yield very high concordance and show a similar clinical sensitivity 370 
and specificity for HSIL+ detection.  (54)  Besides accuracy, other assay 371 
characteristics should be taken into account when the choice of the screening 372 
test is considered. The individual genotyping and the range of targeted 373 
genotypes are factors that may play a role in the determination of the preferred 374 
HPV assay. Objective tools for quality assurance and monitoring of HPV tests 375 
within HPV-based screening programs are warranted. 376 
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 Table 1. Absolute numbers and percentages of positivity for high-risk human 
papillomavirus (hr-HPV) in each diagnostic category. Values are shown in numbers 
and percentages. 
HC2: Hybrid Capture 2, Anyplex: Anyplex TMII HPV28; GP5+/6+: GP5+/6+ PCR-EIA-
RH; LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous 
intraepithelial lesion; CC: cervical cancer. * Women with squamous cell carcinoma and 














valid HPV samples 295 290 281 294 239 
Negative 42/164 (25.6%) 37/161 (23.0%) 38/159 (23.9%) 20/163 (12.3%) 21/120 (17.5%) 
LSIL 68/78 (87.2%) 55/76 (72.4%) 60/70 (77.9%) 32/78 (41.0%) 47/67 (70.1%) 
HSIL 44/44 (100.0%) 39/44 (88.6%) 37/44 (84.1%) 35/44 (79.5%) 33/43 (76.7%) 
CC* 7/9 (77.8%) 7/9 (77.8%) 6/8 (75.0%) 6/9 (66.7%) 7/9 (77.8%) 
Table 2. Sensitivity, specificity, and positive and negative predictive values (PPV and 
NPV) for high-grade intraepithelial lesion or carcinoma (HSIL+) of high-risk human 
papillomavirus (hr-HPV) detected with Hybrid Capture 2 (HC2), AnyplexTMII HPV28, 
Linear Array, GP5+/6+ PCR-EIA-RH and CLART2, assay tests.  
 




 HC2 Anyplex Linear Array GP5+/6+  CLART2 
 % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) 
Sensitivity 96.1  (87.0-98.9) 86.8 (74.7-93.3) 86.0 (73.8-93.0) 78.8 (66.0-88.0) 76.5 (63.2-86.0) 
Specificity 54.8 (48.5-60.9) 61.4 (55.1-67.4) 61.2 (54.8-67.2) 73.7 (67.8-79.0) 62.9 (55.8-69.5) 
PPV 31.4 (24.7-39.0) 33.1 (25.7-41.4) 32.3 (25.0-40.7) 39.4 (30.6-49.0) 36.1 (27.7-45.5) 
NPV 98.5 (94.7-99.6) 95.4 (90.8-97.8) 95.3 (90.6-97.7) 94.1 (89.8-96.7) 90.7 (84.4-94.6) 
Table 3. Human papillomavirus (HPV) type-specific results obtained with each test 
compared to Annyplex TMII HPV28.  
 
Anyplex n Linear Array GP5+/6+ CLART2 
HPV6  5 4 (80.0%) - 3 (60.0%) 
HPV 11 1 1 (100.0%) - 1 (100.0%)  
HPV 16 49 46 (93.4%) 46 (93.4%) 44 (89.8%) 
HPV 18 5 5 (100.0%) 3 (60.0%) 3 (60.0%) 
HPV 31 17 16 (94.1%) 14 (82.4%) 12 (70.6%) 
HPV 33 2 1 (50.0%) 2 (100.0%) 2 (100.0%) 
HPV 35 5 5 (100.0%) 3 (60.0%) 4 (80.0%) 
HPV 39 10 3 (30.0%) 4 (40.0%) 2 (20.0%) 
HPV 40 2 0 (0.0%) - 0 (0.0%) 
HPV 42 17 8 (47.1%) - 0 (0.0%) 
HPV 43 5 - - 0 (0.0%) 
HPV 45 3 3 (100.0%) 2 (66.7%) 1 (33.3%) 
HPV 51 6 5 (83.3%) 2 (33.3%) 6 (100.0%) 
HPV 52 12 11 (91.7%) 2 (16.7%) 10 (83.3%) 
HPV 53 17 14 (82.4%) 0 (0.0%) 10 (58.8%) 
HPV 54 3 3 (100.0%) - 1 (33.3%) 
HPV 56 12 8 (66.7%) 9 (75.0%) 4 (33.3%) 
HPV 58 11 7 (63.6%) 8 (72.7%) 8 (72.7%) 
HPV 59 10 7 (70.0%) 4 (40.0%) 6 (60.0%) 
HPV 61 8 7 (87.5%) - 7 (87.5%) 
HPV 66 10 6 (60.0%) 7 (70.0%) 8 (80.0%) 
HPV 68 8 2 (25.0%) 1 (12.5%) 1 (12.5%) 
HPV 69 1 1 (100.0%) - - 
HPV 70 3 2 (66.7%) - 3 (100.0%) 
HPV 73 7 4 (57.1%) 2 (28.6%) - 
HPV 82 4 1 (25.0%) - 2 (50.0%) 
* Blankets correspond to HPV genotypes not included by each specific tets 
Anyplex: Anyplex TMII HPV28; GP5+/6+: GP5+/6+ PCR-EIA-RH 
Table 4. Risk of positive high-risk human papillomavirus (hr-HPV) test and positive 
result for HPV16 and/or 18 for underlying high-grade intraepithelial lesion or carcinoma 
(HSIL+). Results are shown with odds ratio (OR) and 95% confidence interval (CI). 
HPV test Result OR (95%CI) p 






Anyplex II  Negative 1  
 HPV non 16 non 18 4.3 (1.7-10.9) 0.002 
 HPV16 and/or 18 31.1 (12.1-80.0) <0.001 





 HPV non 16 non 18 
 
3.1 (1.3-7.5) 0.012 
 HPV16 and/or 18 15.3 (6.6-35.8) <0.001 





 HPV non 16 non 18 5.1 (2.0-12.8) 0.001 
 HPV16 and/or 18 23.2 (10.4-53.0) <0.001 
CLART2  Negative 1  
 HPV non 16 non 18 1.8 (0.7-4.5) 0.185 
 HPV16 and/or 18 17.5 (7.5-40.6) <0.001 
HC2: Hybrid Capture 2, Anyplex: Anyplex TMII HPV28; GP5+/6+: GP5+/6+ PCR-EIA-
RH  
